Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, Lotem M, Maurice-Dror C, Hendler D, Rahimian S, Minderman H, Haymaker C, Mahadevan D, Bernatchez C, Murthy R, Hultsch R, Kaplan N, Woodhead G, Hennemeyer C, Chunduru S, Anderson PM, Diab A, Puzanov I. Babiker H, et al. Among authors: minderman h. Clin Cancer Res. 2022 Dec 1;28(23):5079-5087. doi: 10.1158/1078-0432.CCR-21-4486. Clin Cancer Res. 2022. PMID: 35917516 Free PMC article.
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Maguire O, Minderman H, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy-Lagunes D, Shah M. Iyer RV, et al. Among authors: minderman h. Cancer. 2020 Aug 15;126(16):3689-3697. doi: 10.1002/cncr.32994. Epub 2020 Jun 11. Cancer. 2020. PMID: 32525561 Free PMC article. Clinical Trial.
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Fountzilas C, et al. Among authors: minderman h. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. Clin Cancer Res. 2021. PMID: 34645646 Free PMC article. Clinical Trial.
Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR. Qadir M, et al. Among authors: minderman h. Clin Cancer Res. 2005 Mar 15;11(6):2320-6. doi: 10.1158/1078-0432.CCR-04-1725. Clin Cancer Res. 2005. PMID: 15788683
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs.
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura CM, Sander C, Withers H, Long MD, Chavel C, Olejniczak SH, Minderman H, Kirkwood JM, Edwards RP, Storkus WJ, Romero P, Kalinski P. Dong B, et al. Among authors: minderman h. Cancer Immunol Res. 2024 Oct 1;12(10):1421-1437. doi: 10.1158/2326-6066.CIR-24-0061. Cancer Immunol Res. 2024. PMID: 38949179
An Immunosuppressive Effect of Melanoma-derived Exosomes on NY-ESO-1 Antigen-specific Human CD8+ T Cells is Dependent on IL-10 and Independent of BRAFV600E Mutation in Melanoma Cell Lines.
Shu S, Matsuzaki J, Want MY, Conway A, Benjamin-Davalos S, Allen CL, Koroleva M, Battaglia S, Odunsi A, Minderman H, Ernstoff MS. Shu S, et al. Among authors: minderman h. Immunol Invest. 2020 Oct;49(7):744-757. doi: 10.1080/08820139.2020.1803353. Epub 2020 Aug 17. Immunol Invest. 2020. PMID: 32799717 Free PMC article.
84 results